Roche's Dry AMD Drug Lampalizumab Delivers Disappointment In Phase III
Analysts had already been doubtful about the prospects for success in the Spectri study. A second Phase III trial is ongoing, but the candidate is already being removed from revenue models.
You may also be interested in...
Apellis Says Mixed Phase III Results Position Geographic Atrophy Candidate For Filing
Apellis plans to file pegcetacoplan for approval as the first drug to treat the advanced AMD condition geographic atrophy, despite the C3 inhibitor hitting its endpoint in only one of two pivotal trials.
Gyroscope Merger Creates Gene Therapy Biotech For Eye Disorders
A new UK/US biotech tie-up makes a company with the technology to deliver its gene therapies.
Roche Bi-Specific Antibody Has Eylea In Its Sights After Lucentis Win
Following the failure late last year of Regeneron's combination of Eylea with nesvacumab, a Phase II success for the Swiss major's RG7716 is a boost for the theory that a VEGF/Ang-2 combo therapy can transform the treatment of certain eye diseases.